NCT06558227

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
BIOLOGICAL	ZG005 for Injection	10 mg/kg or 20 mg/kg administered intravenously Q3w
BIOLOGICAL	Bevacizumab	15 mg/kg administered intravenously Q3w
BIOLOGICAL	Sintilimab	200 mg administered intravenously Q3w
BIOLOGICAL	Bevacizumab	15 mg/kg administered intravenously Q3w

Timeline

• Start date: 2024-10-24
• Primary completion: 2026-09-01
• Completion: 2026-10-01
• First posted: 2024-08-16
• Last updated: 2024-12-16

Locations

1 site across 1 country: China